Schedule 13G ownership disclosure
Context Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 21077P108
Event date: 2025-12-31
- Filing-level shares
- 10,679,391.00
- Percent of class
- 11.6%
- MPM BioImpact LLC
Shares: 10,679,391.00 · Class: 11.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001687078-26-000005
- Form type
- SCHEDULE 13G/A
- Filer
- Context Therapeutics Inc.
- CIK
- CIK 1842952
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership